Neovacs has formed a collaboration with Professor Robert Kerbel and his team at the Sunnybrook Research Institute of Toronto, Canada for preclinical development of Neovacs’ VEGF Kinoid, specifically to obtain the proof of concept for the treatment of colorectal and ovarian cancer. The Neovacs technology presents a new therapeutic opportunity for these types of cancers where the VEGF-A (vascular endothelial growth factor) protein plays an important role in the vascularization of the tumor. The...